Short communication · 29 Aug 2026
Conference abstractPublished 20 Jun 2022
Use of Biologics in Management of Atopic Eczema
University of Liverpool, United Kingdom
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Atopic dermatitis (AD) is a common inflammatory skin disease distinguished by intense pruritus, and excoriations. Most can be treated with topical agents. Some requires systemic therapy; however they have multiple adverse effects and limited efficacy. Dupilumab is the first targeted biologic agent, recently approved for the treatment of moderate-to-severe AD. It is a fully-human monoclonal antibody and blocks the shared IL-4 receptor which is proposed to be a critical pathway in allergic diseases. Methods: A search through Pubmed, Medline, DermNet, BAD Journals, Uptodate, and Embase was performed on use of dupilumab in treating moderate-to-severe AD. The articles found were reviewed and analysed. Results: The efficacies of different dupilumab doses were analysed and it showed that patients treated with dupilumab 300 mg weekly had similar clinical outcomes to those receiving 300 mg every alternate week. Therefore, NICE Guidance has recommended a dose of dupilumab every alternate week so as to be cost-effective in the NHS. Its safety profile is considered superior to that of immunosuppressive drugs, as it specifically blocks signals from IL-4 and IL-13 only. Common side effects of dupilumab are conjunctivitis, headaches and cold sores. Conclusion: The recommended criteria on indications to initiate Dupilumab treatment for moderateto-severe AD in adults is when the disease has not responded adequately to at least one other systemic therapy, or these are contraindicated or not tolerated. An adequate response is seen if there is at least 50% reduction in the EASI 50 at least a 4-point reduction in the DLQI from initiation of treatment.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Dermatology and Dermatologic Diseases.
Conference abstract · 15 Jun 2026
Cellular Mechanisms of Skin Aging and Regenerative Dermatology: From Molecular Biology to Clinical Practice
Conference abstract · 15 Jun 2026
Innovative Approaches in Acne Management and Cosmetic Dermatology: From Molecular Mechanisms to Personalized Therapy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Dermatology and Dermatologic Diseases
- SubjectDermatology
- BylineArticles whose byline prints “Adlene Adnan”
